Revance Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
We're happy to have Revance here with us. We have the CEO, Dan Browne, with us (inaudible). So he's going to (inaudible).
Great. [Jason], thank you. Good afternoon, everyone, and thank you for joining us for a short conversation on Revance. This is an exciting time for the company as we look at putting ourselves in position to file our -- for our first approval here in the next several months and looking forward to launching the product next year.
On Slide 2, I'll be making some forward-looking statements. So I would ask each of you to look at this at your earliest opportunity.
Since we're working from the hard copy today, I just wanted to sort of highlight on Slide 3, the investments that we see looking at opportunities to create meaningful value in 3 distinct pillars of our business. First is the use of these very potent neuromodulators in aesthetics; further opportunities to create value on a therapeutic in a number of both neurologic and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |